Welcome reception

Welcome Address
Saad Usmani, Faith Davies

Session 1: Defining High-Risk MM
Chairs: Faith Davies, Ken Anderson

• New classification for identifying high-risk multiple myeloma based on cytogenetic abnormalities: Faith Davies
• Using genomics to predict high-risk multiple myeloma: Francesco Maura
• Too much for T cells! What defines high-risk disease in the era of T cell redirecting therapy?: Simon Harrison
• Frailty: A high-risk feature in MM: Hira Mian
• Future directions in defining HRMM by genomics, immunomics, and microenvironment: Ken Anderson
• Definition and outcomes of high-risk multiple myeloma in recent clinical trials: Pieter Sonneveld

Panel Discussion

Coffee Break

Session 2: Extramedullary Disease Biology
Chairs: Benjamin Barwick & Hira Mian

• Extramedullary disease versus paramedullary disease – is there a biological difference?: Faith Davies
• Stromal interaction related gene expression changes recapitulate the transcriptional program of extramedullary disease: Mehmet Samur
• The role of imaging in the management of extramedullary disease: Elena Zamagni

Panel Discussion

 

Session 3: MMSET Disease Subset
Chairs: Mattia D’Agostino & Jonathan Licht

• Direct and indirect targeting of MMSET in t(4;14) myeloma: Jonathan Licht
• Prognostic impact of t(4;14), alone and in combination with other genomic risk factors: Kylee Maclachlan
• Targeting epigenetic dysregulation in t(4;14) multiple myeloma: Benjamin Barwick

Panel Discussion

Lunch

Session 4: Circulating Malignant Plasma Cells Biology
Chairs: Gareth Morgan & Saad Usmani

• Genomics drivers of the adverse biology of circulating plasma cells: Gareth Morgan
• Circulating tumor cells in multiple myeloma: Irene Ghobrial
• The potential of liquid biopsies to track and understand disease dissemination: Juan Jose Garces

Panel Discussion

 

Session 5: Immuno- and Targeted Therapies and Data in High Risk (Part 1)
Chairs: Peter Voorhees & Thomas Martin

• Do bispecifics work better for any high-risk subsets: Saad Usmani
• How to optimize bispecific antibodies for better outcomes in high-risk MM: Ajai Chari
• Resistance to bispecific antibodies: High-risk immune profile: Niels van de Donk

Panel Discussion

Coffee Break

Session 6: Immuno- and Targeted Therapies and Data in High Risk (Part 2)
Chairs: Ross Firestone & Hearn Jay Cho

• Novel approaches to overcome high-risk myeloma: Samir Parekh
• The role of CELMoDs in management of high-risk disease: Nisha Joseph
• The role of ADCs in the management of high-risk myeloma: Peter Voorhees

Panel Discussion

Session 7: CAR Therapies and Data in High Risk
Chairs: Krina Patel & Ajai Chari

• Allogeneic cell therapy platforms: Karlo Perica
• CAR T-cell therapy for functional high risk patients: Suboptimal responders and early relapse: Roberto Mina
• Does CAR T-cell therapy work for patients with EMD, PCL, CNS disease and other high-risk features? Is one-and-done the right approach?: Krina Patel

Panel Discussion

Conclusions & End of Day 1

Welcome to Day 2

Session 8: MAF/MAFB Disease
Chairs: Rafael Fonseca & Brian Walker

• Chromatin mechanisms of myeloma initiation by oncogenic MAF: Anastasios Karadimitris
• Immune microenvironment changes driven by high-risk genetic lesions across MM subtypes: José Ángel Martínez Climent
• C-eeing a MAF or B-eing A-MAF phenotype variant: Jonathan Keats

Panel Discussion

Session 9: Designing Single-Arm Studies in High-Risk MM
Chairs: Leif Bergsagel, Martin Kaiser

• Incorporating novel therapies and innovative trial designs for high risk newly diagnosed multiple myeloma: Sham Mailankody
• Maximizing the activity of cell-cycle specific chemotherapy to treat HRMM: Leif Bergsagel
• Bispecific antibody-based combination therapy for high-risk TE-ND MM: Marc Raab
• External comparator arm trials for high-risk myeloma patients: The OPTIMUM/MUKnine experience: Martin Kaiser

Panel Discussion

Break

Session 10: Designing Randomized Studies in High-Risk MM
Chairs: Francesca Gay & Robert Orlowski

• The journey towards randomized studies: I want to know what high risk is: Robert Orlowski
• Practical aspects in designing randomized studies in high-risk MM: Francesca Gay
• Early immunotherapy deployment to overcome biologic and dynamic high-risk multiple myeloma: Binod Dhakal
  
• Creating global academic trials in high-risk MM: Shaji Kumar

Panel Discussion

Meeting Conclusions

Lunch and adjourn